OrganiGram Holdings Inc., through its subsidiaries, produces and sells dried cannabis and cannabis oil in Canada. It also offers wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis oils to retailers and wholesalers. The company also exports its products. It sells its products online, as well as through phone orders. OrganiGram Holdings Inc. was founded in 2013 and is headquartered in Moncton, Canada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone1-855-961-9420
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$61.27 million
Profitability
Miscellaneous
Employees615
Next Earnings Date1/27/2020 (Estimated)
OptionableNot Optionable
OrganiGram (NASDAQ:OGI) Frequently Asked Questions
What is OrganiGram's stock symbol?
OrganiGram trades on the NASDAQ under the ticker symbol "OGI."
How were OrganiGram's earnings last quarter?
OrganiGram Holdings Inc (NASDAQ:OGI) posted its quarterly earnings data on Monday, July, 15th. The company reported ($0.07) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.02 by $0.09. The business earned $30.36 million during the quarter, compared to the consensus estimate of $30.81 million. OrganiGram had a negative return on equity of 7.21% and a negative net margin of 11.16%. OrganiGram's revenue was up 782.6% on a year-over-year basis. View OrganiGram's Earnings History.
When is OrganiGram's next earnings date?
What price target have analysts set for OGI?
9 brokers have issued 12-month target prices for OrganiGram's stock. Their forecasts range from $8.20 to $17.10. On average, they expect OrganiGram's stock price to reach $10.96 in the next year. This suggests a possible upside of 307.4% from the stock's current price. View Analyst Price Targets for OrganiGram.
What is the consensus analysts' recommendation for OrganiGram?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OrganiGram in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OrganiGram.
Has OrganiGram been receiving favorable news coverage?
News articles about OGI stock have trended somewhat negative recently, InfoTrie reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. OrganiGram earned a news impact score of -1.2 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for OrganiGram.
Are investors shorting OrganiGram?
OrganiGram saw a increase in short interest in October. As of October 15th, there was short interest totalling 4,280,000 shares, an increase of 46.1% from the September 15th total of 2,930,000 shares. Based on an average daily volume of 1,300,000 shares, the short-interest ratio is presently 3.3 days. Approximately 2.9% of the shares of the stock are sold short. View OrganiGram's Current Options Chain.
Who are some of OrganiGram's key competitors?
Some companies that are related to OrganiGram include Karuna Therapeutics (KRTX), Alder Biopharmaceuticals (ALDR), Axsome Therapeutics (AXSM), Apellis Pharmaceuticals (APLS), Corcept Therapeutics (CORT), Myovant Sciences (MYOV), Constellation Pharmaceuticals (CNST), Aurinia Pharmaceuticals (AUPH), Nabriva Therapeutics (NBRV), Athenex (ATNX), Esperion Therapeutics (ESPR), Innoviva (INVA), Y-mAbs Therapeutics (YMAB), Arvinas (ARVN) and Enanta Pharmaceuticals (ENTA).
What other stocks do shareholders of OrganiGram own?
Who are OrganiGram's key executives?
OrganiGram's management team includes the folowing people:
- Mr. Greg Engel, CEO & Director (Age 54)
- Mr. Paolo De Luca C.A., C.F.A, Chief Financial Officer (Age 46)
- Mr. Jeff Purcell, VP - Operations
- Mr. Timothy Emberg, Sr. VP of Sales & Commercial Operations
- Mr. Peter R. Hanson, Director of Fin.
Who are OrganiGram's major shareholders?
OrganiGram's stock is owned by many different of retail and institutional investors. Top institutional investors include Ancora Advisors LLC (0.21%), Commonwealth Equity Services LLC (0.06%), Sigma Planning Corp (0.04%), Penserra Capital Management LLC (0.04%), Cambridge Investment Research Advisors Inc. (0.02%) and Traynor Capital Management Inc. (0.02%).
Which institutional investors are selling OrganiGram stock?
OGI stock was sold by a variety of institutional investors in the last quarter, including Ancora Advisors LLC and Virtu Financial LLC.
Which institutional investors are buying OrganiGram stock?
OGI stock was bought by a variety of institutional investors in the last quarter, including Sigma Planning Corp, Penserra Capital Management LLC, Cambridge Investment Research Advisors Inc., Signition LP, Millennium Management LLC, Archford Capital Strategies LLC, Wedbush Securities Inc. and Commonwealth Equity Services LLC.
How do I buy shares of OrganiGram?
Shares of OGI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is OrganiGram's stock price today?
One share of OGI stock can currently be purchased for approximately $2.69.
How big of a company is OrganiGram?
OrganiGram has a market capitalization of $420.12 million and generates $61.27 million in revenue each year. The company earns $-7,200,000.00 in net income (profit) each year or $0.06 on an earnings per share basis. OrganiGram employs 615 workers across the globe.View Additional Information About OrganiGram.
What is OrganiGram's official website?
How can I contact OrganiGram?
OrganiGram's mailing address is 35 English Dr., Moncton Z4, E1E 3X3. The company can be reached via phone at 1-855-961-9420.
MarketBeat Community Rating for OrganiGram (NASDAQ OGI)
MarketBeat's community ratings are surveys of what our community members think about OrganiGram and other stocks. Vote "Outperform" if you believe OGI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OGI will underperform the S&P 500 over the long term. You may vote once every thirty days.
